Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-LineRASWild-Type Metastatic Colorectal Cancer

(2018) Andrew G. Hill et al.   CLINICAL CANCER RESEARCH

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.

(2018) Takahiro Kogawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

(2018) Yasutaka Sukawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer

(2017) Kimio Yonesaka et al.   LUNG CANCER

HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy

(2016) Hisato Kawakami et al.   Recent Patents on Anti-Cancer Drug Discovery

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

(2016) Yoshikane Nonagase et al.   Oncotarget

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

(2015) K Yonesaka et al.   ONCOGENE

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

(2015) Hisato Kawakami et al.   Oncotarget

ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays

(2014) Camilo Guzmán et al.   PLoS One

RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

(2013) C. Mirschberger et al.   CANCER RESEARCH

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

(2013) A. P. Garner et al.   CANCER RESEARCH

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy

(2012) Amye J. Tevaarwerk et al.   CANCER

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function

(2012) J. T. Garrett et al.   CLINICAL CANCER RESEARCH

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

(2010) Katri Köninki et al.   CANCER LETTERS

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

(2010) B. Schoeberl et al.   CANCER RESEARCH

The EGF/CSF-1 Paracrine Invasion Loop Can Be Triggered by Heregulin  1 and CXCL12

(2009) L. Hernandez et al.   CANCER RESEARCH

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY